VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL

Salim Yazji, MD, Oncternal Therapeutics, San Diego, CA, comments on the rationale and design of ZILO-301, a Phase III study comparing the safety and efficacy of zilovertamab plus ibrutinib vs ibrutinib alone in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) (NCT05431179). Dr Yazji also briefly talks on a ROR1-directed CAR-T therapy that is currently being developed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Oncternal Therapeutics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter